Latest News

Sibylla Biotech Enters a Strategic Drug Discovery Collaboration with Ono Pharmaceutical in Central Nervous System Disorders   Milan, Italy, March 14, 2024 – Sibylla Biotech announced today a drug discovery collaboration with Ono Pharmaceutical Co., Ltd. (TSE: […]

Naperville, Illinois, USA.  5 March 2024.  Endotronix, Inc., a privately held company dedicated to advancing the treatment of heart failure (HF) at the intersection of digital health and medtech, presented 6-month results from its PROACTIVE-HF pivotal […]

https://www.pemagazine.fr/ODM2MQ/seroba-life-sciences-porte-son-fonds-iv-a-son-objectif-de-120-m    

Seroba Announces Above Target Final Close of its Fund IV at €123M ($134M). • Seroba, a European life sciences venture capital firm headquartered in Dublin, with offices in Paris and Milan, announces the final close of […]

U.S.-Ireland Specialty Pharmaceutical Company’s ready-to-dilute form of a drug for the treatment of adenocarcinoma of the breast or ovary January 9, 2024 – CAMBRIDGE, Mass. – Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that […]

Naperville, Illinois, USA.   5 January, 2024.  Seroba’s portfolio company, Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced the submission of a Premarket Approval (PMA) […]

 Biotech Finances 11 December 2023 LE FONDS IRLANDAIS SEROBA CONFIRME SES AMBITIONS FRANÇAISES, by Pierre Havez    Fondé en 2002 à Dublin, le fonds irlandais Seroba renforce sa présence française afin d’accroître ses investissements sur le […]

Galway, Ireland, 20 December, 2023.  Perfuze, a private medical device company dedicated to developing pioneering technology to treat acute ischemic stroke, proudly announces FDA clearance for the Millipede 070 Aspiration Catheter and the 2nd generation of […]

We use cookies and analytics to improve your online experience and to help us to understand where our audience is and how they reach us, as well as to understand what topics and site features are of greatest interest.  To find out more, please read our Privacy Policy. By clicking on the Accept button, you consent to our use of cookies and browsing analytics.

Scroll to Top